Gallant Pet, Inc.
Ready-to-use stem cell therapies for pets
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2018
- Latest Form D
- $10.2M, Jul 2025
- Total capital
- $42.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $42.6M
- 3 Form D · last Jul 2025
- 16 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 15 pending · first 2020
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$10.2M
- Private capital raisedForm D · SEC · 2nd filing$25.5M
- Private capital raisedForm D · SEC · 1st filing$7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Linda BlackResearcherExecutive Officer, DirectorLinked by 2 patents
- Aaron HirschhornExecutive Officer, DirectorNamed in SEC Form D filings
- Aaron SchachtDirectorNamed in SEC Form D filings
- Darryl RawlingsDirectorNamed in SEC Form D filings
- Davis BrimerExecutive Officer, DirectorNamed in SEC Form D filings
- Doug DrewDirectorNamed in SEC Form D filings
Show all 10 people
- James RatiganDirectorNamed in SEC Form D filings
- Misti UshioDirectorNamed in SEC Form D filings
- Richard JenningsDirectorNamed in SEC Form D filings
- Teymour Boutros-GhaliDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 18- GrantedUterine-derived Regenerative Cell Compositions And Uses ThereofUSPTOUS 12,497,594
- GrantedUterine-derived Regenerative Cell Compositions And Uses ThereofUSPTOUS 12,241,088
- PendingPrimed Uterine-derived Regenerative Cell Compositions And Uses ThereofUSPTOApplication 18707117
Show all 18 patent records
- Uterine-derived Regenerative Cell Compositions And Uses ThereofDec 16, 2025 · US 12,497,594Granted
- Uterine-derived Regenerative Cell Compositions And Uses ThereofMar 4, 2025 · US 12,241,088Granted
- Primed Uterine-derived Regenerative Cell Compositions And Uses ThereofJan 16, 2025 · Application 18707117Pending
- Methods For Optimizing Reproductive Tissue Derived Cell Yield And Viability For Clinical ApplicationsOct 24, 2024 · Application 18262069Pending
- Systemic, Allogenic Stem Cell Therapies For Treatment Of Diseases In AnimalsMar 31, 2022 · Application 17302747Pending
- Uses Of Trehalose In Cell SuspensionsAug 19, 2021 · Application 17302633Pending
- Viable Cell Compositions, And Methods Related To SameDec 10, 2020 · Application 16738870Pending
- Vial Useable In Tissue Extraction ProceduresMay 19, 2020 · US 10,653,397Granted
- Viable Cell Compositions, And Methods Related To SameNov 23, 2017 · Application 15471578Pending
- Systemic, Allogenic Stem Cell Therapies For Treatment Of Diseases In AnimalsJan 19, 2017 · Application 15281291Pending
- Uses Of Trehalose In Cell SuspensionsMar 31, 2016 · Application 14869006Pending
- Methods For Optimizing Reproductive Tissue Derived Cell Yield And Viability For Clinical ApplicationsApplication 63139031Pending
- Primed Uterine-derived Regenerative Cell Compositions And Uses ThereofApplication 63263550Pending
- Uterine-derived Regenerative Cell Compositions And Uses ThereofApplication 63022302Pending
- Uterine-derived Regenerative Cell Compositions And Uses Thereof For Clinical ApplicationsApplication 63263548Pending
- Methods For Optimizing Reproductive Tissue Derived Cell Yield And Viability For Clinical ApplicationsApplication PCTUS2022070219Pending
- Primed Uterine-derived Regenerative Cell Compositions And Uses ThereofApplication PCTUS2022048067Pending
- Uterine-derived Regenerative Cell Compositions And Uses ThereofApplication PCTUS2021031148Pending
Related companies, and why
- AeroRx TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Samsara Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- MultiValent Biotherapies, Inc.Similar federal contract value in Biotech · null in contracts
- ImmuneSensor Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Cambrian Genomics, Inc.Similar federal contract value in Biotech · null in contracts
- Expanesthetics, IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .